5 May 2023
Latham & Watkins Advises on Reneo Pharmaceuticals’ Public Offering of Common Stock and Concurrent Private Placement
Advising firms
Deal team
4 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Matt Bush Lead | Latham & Watkins LLP | Partner | capital markets | San Diego |
| Raul Gonzalez | Latham & Watkins LLP | Associate | capital markets | Bay Area |
| Peter Simon | Latham & Watkins LLP | Associate | capital markets | San Diego |
| Sterling Swift | Latham & Watkins LLP | Associate | capital markets | San Diego |
1 more lawyer on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 55m (US$55.0 million)
- What the figure measures
- Issue size
- Client
- Reneo Pharmaceuticals, Inc.Issuer
- Counterparties
- Abingworth Bioventures 8 LP (Investor)